ABBOTINDIA25,230.00

Abbott India Ltd.

· Pharma & Health
₹ CrorePeersPFIZERGLAXOIPCALABAJANTPHARMANTHEMMEDANTAGLENMARKBIOCON
Comp Set
In ₹ Crore except Per Share
Latest Annual
ABBOTINDIA
FY26
PFIZER
FY26
GLAXO
FY26
IPCALAB
FY26
Peer
Median
Valuation — at last close
P/E52.42×43.84×48.13×
P/B21.19×5.25×13.22×
EV/EBITDA35.08×25.10×30.09×
Market Cap₹48,417 Cr₹50,032 Cr₹49,225 Cr
Growth
Revenue CAGR 3Y9.01%1.29%5.53%15.60%5.53% +63%
Revenue CAGR 5Y9.96%2.39%3.62%12.22%3.62% +175%
Net Income CAGR 3Y17.80%5.01%19.26%35.20%19.26% -8%
Revenue YoY (latest Q)16.55%20.76%18.66%
Net Income YoY (latest Q)15.69%82.18%48.94%
Profitability
EBITDA Margin27.31%35.88%34.26%20.51%34.26% -20%
Net Income Margin22.40%28.67%27.11%12.27%27.11% -17%
Return on Common Equity32.51%17.19%45.34%11.98%17.19% +89%
Return on Capital Employed36.14%19.71%48.84%15.51%19.71% +83%
Return on Assets23.87%14.68%23.96%9.57%14.68% +63%
Credit & Quality
Total Debt/Equity0.00×0.00×0.07×0.00×
Interest Coverage72.67×89.28×455.22×20.55×89.28× -19%
Scale — latest FY
Revenue / Total Income₹6,929 Cr₹2,520 Cr₹3,822 Cr₹9,646 Cr₹3,822 Cr +81%
Net Income₹1,552 Cr₹722 Cr₹1,036 Cr₹1,184 Cr₹1,036 Cr +50%
Total Assets₹6,502 Cr₹4,922 Cr₹4,324 Cr₹12,370 Cr₹4,922 Cr +32%
EPS₹0₹54.52₹44.98₹49.75 -100%
Book Value per Share₹134.86₹375.41₹255.14
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.